TriSalus Life Sciences, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$35M
↑+47.4% +$11Mvs FY2024
Total Liabilities
$69M
↑+38.8% +$19Mvs FY2024
Cash
$20M
↑+139.8% +$12Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $35M | $24M |
| Current Assets | $32M | $21M |
| Cash | $20M | $9M |
| ST Investments | $0 | $0 |
| Receivables | $7M | $5M |
| Inventory | $3M | $4M |
| Other Current | $2M | $3M |
| Non-Current Assets | $3M | $3M |
| PPE | $0 | $0 |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $3M | $3M |
| Total Liab+Eq | $35M | $24M |
| Current Liab. | $11M | $10M |
| Accounts Payable | $0 | $0 |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $11M | $10M |
| Non-Current Liab. | $58M | $40M |
| Long-Term Debt | $33M | $22M |
| Other LT Liab. | $25M | $18M |
| Equity | $-34M | $-26M |
| Retained Earnings | $331M | $280M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · TLSI · Comparing FY2025 vs FY2024